Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

51 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To investigate the ability of 600 mg of Glivec®, given once daily by mouth to patients with rising PSA following radical prostatectomy, to produce a sustained biochemical response during the first 6 months of treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor

NCT00112632

Gastrointestinal Stromal Tumor

COMPLETED PHASE2

Imatinib Mesylate in Treating Patients With Stage IV Colorectal Cancer

NCT00041340

Recurrent Colon Cancer Recurrent Rectal Cancer Stage IV Colon Cancer +1 more

COMPLETED PHASE2

Safety and Efficacy Evaluation of Two Year Imatinib Treatment in Adjuvant Gastrointestinal Stromal Tumor (GIST)

NCT01172548

Gastrointestinal Stromal Tumors

COMPLETED PHASE2

A Study of Imatinib and Docetaxel in Prostate Cancer

NCT00251225

Prostate Cancer

COMPLETED PHASE2

Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer

NCT00042952

Ovarian Dysgerminoma Recurrent Malignant Testicular Germ Cell Tumor Recurrent Ovarian Germ Cell Tumor +5 more

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prostatic Neoplasm Genital Neoplasms, Male Neoplasms, Abdominal Urogenital Neoplasms Genital Diseases, Male Prostatic Diseases Antineoplastic Agents Imatinib

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

imatinib mesylate

Group Type EXPERIMENTAL

STI571 (Glivec®)

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

STI571 (Glivec®)

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Glivec

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* who are 18 years of age or older.
* who have undergone radical prostatectomy within 2 years prior to PSA progression .
* exhibiting two consecutive rises in PSA levels relative to a previous reference value, separated by 14 days.

The first measurement must occur 14 days after the reference value und must be at least 20% above the reference value. The reference value must be at least 0.4 ng/ml. The second confirmatory measurement taken 14 days after the first measurement must be greater than the first measurement.

* with a Karnofsky Performance Score (KPS) greater than or equal to 90 (Appendix 5).
* with the following hematologic lab values: ANC greater than or equal to 1500/mm3, Hgb greater than or equal to 10g/dL, PLT greater than or equal to 100x109/L.
* with the following biochemistry lab values: total bilirubin \< 1.5 ULN, SGOT, SGPT less than or equal to 2.5 ULN, serum creatinine less than or equal to 1.5 ULN.
* willing to employ an effective barrier method of contraception during the study duration and for 3 months following discontinuation of study drug (for patients of reproductive potential).
* with a life expectancy of \> 6 months.
* who have provided written informed consent pursuant to local regulatory requirements prior to initiation of any study procedure.

with a Gleason Score \> 6 in the prostatectomy specimen

Exclusion Criteria

* with a history of another malignancy within 5 years prior to study entry, except curatively treated non-melanotic skin cancer, unless written approval is obtained by the sponsor.
* with prior hormonal therapy
* who require therapy with warfarin or analgesics of the morphine class or higher (see Section 3.4.4).
* with a known diagnosis of HIV, hepatitis B, or hepatitis C infection.
* who have had a major surgery within 2 weeks prior to study entry.
* with severe, unstable, or uncontrolled medical disease which would confound diagnoses or evaluations required by the protocol, including severe cardiac insufficiency (NYHA III or IV, see Appendix 2), uncontrolled diabetes, chronic hepatic or renal disease, and active uncontrolled infection.
* with a history of noncompliance to medical regimens or inability or unwillingness to return for all scheduled visits.

Minimum Eligible Age

18 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No